How Genomics Is Improving Cancer Screening, Investing May 18, 2021 Cancer remains one of the leading causes of death around the world, but advancements in genomics are enhancing detection and screening capabilities. For investors, that puts the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) at the forefront of vital healthcare developments. Advancements in cancer screening are also part of the broader sustainable investing conversation, indicating the ARK exchange traded fund could check that box for investors too. The early diagnosis of cancer can dramatically improve patient outcomes. “If diagnosed early, cancer often is manageable. In the US, more than 80% of the deaths occur in patients whose cancer already has metastasized prior to the diagnosis,” writes ARK Invest Director of Research Brett Winton. “Researchers estimate that blood tests that diagnose early-stage cancer could reduce the overall cancer mortality rate by more than 25%.”